JPWO2020181235A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2020181235A5
JPWO2020181235A5 JP2021552750A JP2021552750A JPWO2020181235A5 JP WO2020181235 A5 JPWO2020181235 A5 JP WO2020181235A5 JP 2021552750 A JP2021552750 A JP 2021552750A JP 2021552750 A JP2021552750 A JP 2021552750A JP WO2020181235 A5 JPWO2020181235 A5 JP WO2020181235A5
Authority
JP
Japan
Prior art keywords
fusion protein
seq
composition
formula
nos
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021552750A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022524018A5 (https=
JP2022524018A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/021498 external-priority patent/WO2020181235A1/en
Publication of JP2022524018A publication Critical patent/JP2022524018A/ja
Publication of JP2022524018A5 publication Critical patent/JP2022524018A5/ja
Publication of JPWO2020181235A5 publication Critical patent/JPWO2020181235A5/ja
Priority to JP2025176328A priority Critical patent/JP2026016505A/ja
Withdrawn legal-status Critical Current

Links

JP2021552750A 2019-03-06 2020-03-06 Il-10バリアント分子ならびに炎症性疾患および腫瘍を処置する方法 Withdrawn JP2022524018A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025176328A JP2026016505A (ja) 2019-03-06 2025-10-20 Il-10バリアント分子ならびに炎症性疾患および腫瘍を処置する方法

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962814669P 2019-03-06 2019-03-06
US62/814,669 2019-03-06
US201962899504P 2019-09-12 2019-09-12
US62/899,504 2019-09-12
US202062962332P 2020-01-17 2020-01-17
US62/962,332 2020-01-17
PCT/US2020/021498 WO2020181235A1 (en) 2019-03-06 2020-03-06 Il-10 variant molecules and methods of treating inflammatory disease and oncology

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025176328A Division JP2026016505A (ja) 2019-03-06 2025-10-20 Il-10バリアント分子ならびに炎症性疾患および腫瘍を処置する方法

Publications (3)

Publication Number Publication Date
JP2022524018A JP2022524018A (ja) 2022-04-27
JP2022524018A5 JP2022524018A5 (https=) 2023-04-26
JPWO2020181235A5 true JPWO2020181235A5 (https=) 2023-04-26

Family

ID=72334859

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021552750A Withdrawn JP2022524018A (ja) 2019-03-06 2020-03-06 Il-10バリアント分子ならびに炎症性疾患および腫瘍を処置する方法
JP2025176328A Pending JP2026016505A (ja) 2019-03-06 2025-10-20 Il-10バリアント分子ならびに炎症性疾患および腫瘍を処置する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025176328A Pending JP2026016505A (ja) 2019-03-06 2025-10-20 Il-10バリアント分子ならびに炎症性疾患および腫瘍を処置する方法

Country Status (7)

Country Link
US (8) US10858412B2 (https=)
EP (1) EP3934681A4 (https=)
JP (2) JP2022524018A (https=)
KR (1) KR20210139312A (https=)
CN (2) CN114072164A (https=)
CA (1) CA3132385A1 (https=)
WO (1) WO2020181235A1 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10017739B2 (en) * 2012-09-06 2018-07-10 Duke University Methods of expanding and assessing B cells and using expanded B cells to treat disease
JP7641912B2 (ja) 2019-04-19 2025-03-07 シナーキン・ファーマ・ベスローテン・フエンノートシャップ Il13を含む融合タンパク質
WO2021231773A1 (en) 2020-05-13 2021-11-18 Good Therapeutics, Inc. Compositions of protein complexes and methods of use thereof
CA3186753A1 (en) 2020-07-20 2022-01-27 John Mumm Dual cytokine fusion proteins comprising il-10
CN112898436A (zh) * 2020-10-23 2021-06-04 广州医科大学附属肿瘤医院 一种具有靶向功能的鼠pd1和鼠il-15基因融合蛋白的表达及其应用
KR102792982B1 (ko) * 2021-05-28 2025-04-14 한양대학교 산학협력단 세포투과성 펩티드 및 이의 용도
WO2023078245A1 (zh) * 2021-11-02 2023-05-11 广东菲鹏制药股份有限公司 Il10单体融合蛋白及其应用
JP2024546938A (ja) * 2021-12-13 2024-12-26 デカ バイオサイエンシーズ, インコーポレイテッド マルチサブユニットサイトカインを含む二重サイトカイン融合タンパク質
JP2024546999A (ja) * 2021-12-16 2024-12-26 デカ バイオサイエンシーズ, インコーポレイテッド Il-10を含む二重サイトカイン融合物およびがんを処置するための養子細胞療法または二重特異性t細胞エンゲージャー
CN118900697A (zh) 2022-02-22 2024-11-05 德卡生物科学公司 使用白细胞介素减轻双特异性t细胞接合器或嵌合抗原受体t细胞介导的细胞因子释放综合征的方法
CN114632156B (zh) * 2022-05-17 2022-08-16 中国人民解放军军事科学院军事医学研究院 Tim-3在预防、治疗或减轻疼痛中的应用
WO2024097875A1 (en) * 2022-11-02 2024-05-10 Shattuck Labs, Inc. Fusion proteins for the treatment of nonalcoholic steatohepatitis
WO2024123812A1 (en) 2022-12-05 2024-06-13 Shattuck Labs, Inc. Fusion proteins for the treatment of cardiometabolic diseases
WO2024249568A1 (en) 2023-05-30 2024-12-05 Paragon Therapeutics, Inc. Alpha4beta7 integrin antibody compositions and methods of use
CN121889424A (zh) 2023-08-14 2026-04-17 派拉冈医疗公司 α4β7整联蛋白结合蛋白及使用方法
KR20250078792A (ko) * 2023-11-24 2025-06-04 주식회사 메드팩토 피브로넥틴 엑스트라도메인 B (Extradomain B of Fibronectin, EDB-FN) 및 전환성장인자 베타(transforming growth factor β, TGFβ)에 특이적으로 결합하는 융합 단백질 및 이의 용도
CN121108363A (zh) * 2024-06-12 2025-12-12 广东菲鹏制药股份有限公司 一种融合蛋白及其用途
CN119613546B (zh) * 2025-02-10 2025-05-13 细胞生态海河实验室 Il-10抗体及其应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA200802289A1 (ru) * 2006-05-08 2009-04-28 Филоджен Спа Направляемые к мишени антителами цитокины для терапии
ES2536772T3 (es) * 2007-09-21 2015-05-28 The Regents Of The University Of California El interferón dirigido demuestra potentes actividades apoptóticas y antitumorales
WO2009056268A1 (en) * 2007-10-30 2009-05-07 Philogen S.P.A. An antigen associated with rheumatoid arthritis
NZ592420A (en) * 2008-10-02 2012-12-21 Emergent Product Dev Seattle Cd86 antagonist multi-target binding proteins
WO2012045334A1 (en) * 2010-10-05 2012-04-12 Synthon Bv Biologically active il-10 fusion proteins
EA201892619A1 (ru) * 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
CA2876285A1 (en) 2012-08-08 2014-02-13 Roche Glycart Ag Interleukin-10 fusion proteins and uses thereof
RU2612878C2 (ru) * 2012-10-03 2017-03-13 Филоджен С.П.А. Антигены, ассоциированные с воспалительным заболеванием кишечника
KR20160043927A (ko) 2013-03-14 2016-04-22 파카쉬 길 세포 표면 grp78에 결합하는 항체를 사용하는 암 치료
WO2015117930A1 (en) * 2014-02-06 2015-08-13 F. Hoffmann-La Roche Ag Interleukine 10 immunoconjugates
CN104403004B (zh) * 2014-11-24 2017-10-13 苏州丁孚靶点生物技术有限公司 抗体‑干扰素异二聚体的制备和用途
AU2015364396B2 (en) * 2014-12-19 2018-08-09 Alkermes, Inc. Single chain Fc fusion proteins
WO2017091611A1 (en) * 2015-11-23 2017-06-01 Immungene, Inc Enhanced cancer immunotherapy using antibody-interferon fusion molecules
UY37003A (es) * 2015-12-04 2017-06-30 Novartis Ag Composiciones de anticuerpo injertado con citoquina y métodos para su uso en inmunorregulacion

Similar Documents

Publication Publication Date Title
JPWO2020181235A5 (https=)
IL300062A (en) Dual fused cytokine proteins containing IL-10
RU2451689C2 (ru) Новые антипролиферативные антитела
JP2023022186A5 (https=)
Logtenberg Antibody cocktails: next-generation biopharmaceuticals with improved potency
US7960145B2 (en) Compositions and methods for generating antibodies
JP2021516974A5 (https=)
JP2026063140A (ja) 二機能性抗pd-1/il-7分子
JP2021516976A5 (https=)
JP7164528B2 (ja) Pd-1に特異的に結合する可能な抗体及びその機能的断片
Asano et al. Domain order of a bispecific diabody dramatically enhances its antitumor activity beyond structural format conversion: the case of the hEx3 diabody
JP6972022B2 (ja) グルタミンシンセターゼ遺伝子内相補ベクターを用いた高レベルのヘテロマータンパク質発現細胞の直接選択
Roselli et al. CAR-T Engineering: Optimizing Signal Transduction and Effector Mechanisms: E. Roselli et al.
IL313525A (en) Dual cytokine fusion proteins containing multisubunit cytokines
KR950016781A (ko) 면역접합체
RU2013120302A (ru) Сконструированные нуклеиновые кислоты и способы их применения
PL215168B1 (pl) Formulacja polipeptydowa
JP2020522254A (ja) 骨髄増殖性白血病(mpl)タンパク質に結合する多特異性分子およびその使用
RU2015104625A (ru) СПОСОБ ПОЛУЧЕНИЯ РАСТВОРИМОГО FcR В ВИДЕ Fc-ГИБРИДА С ИНЕРТНОЙ Fc-ОБЛАСТЬЮ ИММУНОГЛОБУЛИНА И ИХ ПРИМЕНЕНИЯ
RU2013106217A (ru) Гибридный белок из антитела против мнс и противовирусного цитокина
US20240059798A1 (en) Conditionally activated antigen binding polypeptide complexes and methods of use thereof
CN105229036A (zh) 在疏水性相互作用位点内引入了静电相互作用的蛋白及其制备方法
Huang et al. Recombinant immunotherapeutics: current state and perspectives regarding the feasibility and market
JP2024515263A (ja) 改善された特性を有する二機能性分子のための新規足場構造
Shinde et al. Polyvalency: an emerging trend in the development of clinical antibodies